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Abstract 
Background: Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, 
with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma.
Case presentation: A 62-year old woman diagnosed with severe eosinophilic asthma showed poor response to 
Mepolizumab therapy (100 mg subcutaneous dose/monthly) and subsequent worsening of symptoms. The treat-
ment response to Mepolizumab was monitored using both blood and sputum eosinophil counts. The latter was 
superior in assessing deterioration in symptoms, suggesting that normal blood eosinophil count may not always 
indicate amelioration or adequate control of the ongoing eosinophil-driven disease process. This perplexing situa-
tion of persistent airway eosinophilia and increased steroid insensitivity despite an anti-eosinophil therapy can be 
explained if the administered dose of the mAb was inadequate in comparison to the target antigen. The resultant 
immune complexes could act as ‘cytokine depots’, protecting the potency of the ‘bound’ IL-5, thereby sustaining the 
eosinophilic inflammation within the target tissue. Molecular analysis of the sputum indicated the development of a 
polyclonal autoimmune response as well as an increase in group 2 innate lymphoid cells, two novel observations in 
severe eosinophilic asthma, which were associated with indices of disease severity and progression. This case high-
lights the possibility of a previously unrecognised autoimmune-mediated worsening of asthma perhaps triggered by 
immune complexes formed due to inadequate dosing of administered monoclonal antibodies in the target tissue.
Conclusions: While anti-IL5 mAb therapy is an exciting novel option to treat patients with severe asthma, there is the 
rare possibility of worsening of asthma as observed in this case study, due to local autoimmune mechanisms precipi-
tated by potential inadequate airway levels of the monoclonal antibody.
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Background
The past decade has witnessed the development of sev-
eral anti-cytokine monoclonal antibody therapies (mAb) 
for asthma, with Mepolizumab, an IgG1 mAb against 
IL-5, being the first biologic approved for severe eosin-
ophilic asthma [1]. We report a worrying scenario of 
asthma worsening, following 100 mg subcutaneous (s.c) 
Mepolizumab therapy in a patient with severe eosino-
philic asthma. In this article we draw attention to two 
factors: (i) enumerating eosinophils in sputum is more 
useful to monitor treatment response than in blood; (ii) 
low-dose mAb therapy might lead to increased inflam-
mation triggered by in vivo immune complex (IC) forma-
tion between drug and the target cytokine (IL-5), when 
the latter is in excess to the former in the target tissue. 
This is more likely to affect patients whose asthma is 
severe enough to require maintenance systemic corticos-
teroids to control their airway eosinophilia.
Open Access
Allergy, Asthma & Clinical Immunology
*Correspondence:  parames@mcmaster.ca 
4 Firestone Institute for Respiratory Health, 50 Charlton Avenue East, 
Hamilton, ON L8N 4A6, Canada
Full list of author information is available at the end of the article
Page 2 of 6Mukherjee et al. Allergy Asthma Clin Immunol  (2017) 13:2 
Case presentation
A 62-year old non-atopic woman, with seven pack-year 
smoking history, and adult-onset asthma (diagnosed at 
21 years) whose symptoms worsened at the age of 55 was 
seen in our clinic on February 22nd, 2010 with severe air-
way hyper-responsiveness (PC20 methacholine <0.03 mg/
mL), mild airflow obstruction (FEV1 2.04  L, 75% pre-
dicted, FEV1/VC 75%), and chronic rhinosinusitis with 
polyposis. The eosinophilic nature of her asthma was con-
firmed by peripheral blood counts (peaked at 0.8 × 109/L 
in 2010) and sputum cellularity (eosinophils >3% of total 
cell count with free granules on multiple occasions). She 
did not have mutations for PDGFR-FIP1L1, c-kit, JAK2, 
or BCR-Abl or abnormal lymphocyte population or T cell 
receptor rearrangements. Her routine chemistry, total 
serum IgE, and tryptase were normal, as were her stool 
microscopy, antifungal precipitins, and autoantibody 
profile including cytoplasmic and perinuclear anti-neu-
trophil cytoplasmic antibodies. Computed tomography 
of thorax was unremarkable. She had two sinus polypec-
tomies that did not improve her respiratory symptoms 
significantly. She has been prednisone-dependent since 
2008. Methotrexate, hydroxyurea, and imatinib were not 
effective to wean her off prednisone (Fig. 1). The patient 
was known to be compliant with her medications, and 
her inhaler technique was deemed adequate.
By 2013, she required a daily dose of 2500 mcg flu-
ticasone propionate, long-acting beta-2 agonists, 
muscarinic antagonists, and 20  mg prednisone to 
maintain an FEV1 of 1.76  L (65% of predicted), blood 
eosinophils 0.03 × 109 cells/L, and 4% sputum eosino-
phils (Fig. 1a). With four exacerbations in the preceding 
year, she was enrolled into a double-blinded placebo 
controlled Mepolizumab clinical trial (#MEA115575) 
(in which she received the active drug), followed by an 
open-label extension (#MEA115661). In the double-
blinded trial, her FEV1 was 1.76 L at the start of the 
study (Feb-13) that dropped to 0.9 L at the end of the 
study (Aug-13), with no demonstrable steroid-spar-
ing effect (Fig.  1a). In the open-label extension, she 
received nine monthly infusions of 100 mg s.c Mepoli-
zumab, without an improvement in her FEV1, and two 
interim courses of intravenous solumedrol to man-
age her deteriorating symptoms. The anti-eosinophil 
effect of Mepolizumab was apparent from her deplet-
ing blood eosinophil levels and her sputum eosino-
phils being maintained below 3% until September 
2013 (Fig. 1a). The initial drop in her FEV1 was there-
fore not eosinophil-driven, indicating the presence of 
alternative mechanisms. Furthermore, her lung func-
tion continued to deteriorate with increasing airway 
eosinophilia (not reflected in blood), and prednisone 
requirement that now doubled from a pre-study dose 
of 20–40 mg daily (Fig. 1b). The patient did not develop 
any circulating anti-Mepolizumab antibodies that 
could explain this.
Fig. 1 Disease progression timeline of treatments, development of autoimmune response and clinical severity indices. a FEV1 and blood eosino-
phils (109/L) is plotted on the left Y axis, while sputum eosinophil % on the right Y axis for the given time points. Dotted line represents the upper-
limit of normal blood eosinophil level. b Association of FEV1 and sputum anti-EPX IgG (see Additional file 1: online repository for methods) is plotted 
on the left Y axis, while daily prednisone dose is plotted on the right Y axis. For both, black arrow indicates intravenous solumedrol (except last 
indicated on Jan-16 refers to 40 mg prednisone burst, tapered down to maintenance 17.5 mg dose)
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Discussion and molecular insights
Mepolizumab is an effective therapy to reduce blood 
and sputum eosinophils in severe prednisone-depend-
ent asthma, with a good safety profile and low incidence 
of circulating anti-drug antibodies [1–3]. However, 
the magnitude of clinical efficacy may be lower regard-
ing prednisone-sparing effect with 100  mg of the drug 
administered subcutaneously compared to 750 mg intra-
venously. This may be due to inadequate concentrations 
of the drug in the airway. We are unable to confirm this 
as the mAb pharmacokinetics in the airway of asthmat-
ics has not been established. It is plausible, in the event 
of inadequate dosing in the airways of patients with high 
IL-5 concentration, drug-antigen IC clusters can form 
(Additional file  1: Figure S1 in the online repository). 
Being an IgG1 humanised mAb, the IL-5/Mepolizumab 
ICs, can precipitate, bind complement and elicit further 
inflammation and tissue injury. In the complexed form, a 
neutralising mAb protects the active-site of the cytokine 
from in  vivo degradation [4]. This increases the bio-
availability of IL-5 to its target receptors present on tis-
sue-resident cells like ILC2s and eosinophil progenitors 
(EoPs). Enumeration of both these cell types was recently 
reported to be significantly higher in severe asthmatic 
airways [5].
This case study offered us a unique opportunity to 
investigate this hypothesis of an IC-mediated worsen-
ing of patient symptoms in the event of inadequate mAb 
dosing. Due to unavailability of a biopsy sample, tissue 
deposition of ICs could not be performed. An attempt 
to quantify complement consumption in the sputum to 
assess local IC formations was inconclusive. The assay 
performance with sputum supernatants was unreliable in 
comparison to other biological samples like nasal polyp 
extracts performed alongside. Nevertheless, a series of 
molecular investigations were undertaken to answer this 
perplexing situation of persistent airway eosinophilia 
(but normal blood eosinophil) while on treatment with 
Mepolizumab, deteriorating lung function and subse-
quent increase in steroid-insensitivity.
Our molecular studies demonstrated that sputum IL-5 
levels peaked at the end of her Mepolizumab therapy 
(Fig. 2). This increase in IL-5 during an anti-IL5 therapy, 
along with demonstrable sputum eosinophils, can be 
explained by IL-5/Mepolizumab ICs acting as ‘cytokine 
depots.’ Early studies in murine models from the 1990s 
report that cytokine: anti-cytokine complexes exhibit 
increased in  vivo half-lives, functional potency, and 
downstream biological activity of the bound cytokine [4]. 
This increase in in  vivo potency/downstream biological 
activity by cytokine: anti-cytokine mAb complexes has 
been demonstrated for several cytokines viz., IL-2 [6], 
IL-4 [7], IL-6 [8], IL-7 [9]. Indeed, by using a sandwich 
ELISA (see Additional file 1: online repository for meth-
ods), we could detect IL-5 bound to immunoglobu-
lins immunoprecipitated from the sputum supernatant 
induced at the Aug-2013 visit, post 6 infusions (Visit 9, 
#MEA115575), otherwise undetectable in prior samples 
(Additional file 1: Figure S2).
We enumerated IL-5+ ILC2 cells by flow cytometry in 
both blood and sputum. There was a dramatic increase 
in circulating IL5+ ILC2 s after six injections of Mepoli-
zumab (Aug-13, Fig. 2). By Apr-14, sputum IL5+ ILC2 s 
was demonstrable despite further nine infusions of s.c 
100  mg Mepolizumab (Fig.  2). A recent study investi-
gated the cause of rare eosinophilia post-low dose IL-2 
therapy in HCV-induced vasculitis. This was shown to be 
an IL-2/anti-IL-2 mAb (IC)-mediated mechanism where 
the increased bioavailability of the bound IL-2 favoured 
interactions with IL-2R expressed by ILC2  s, stimulat-
ing in  situ IL-5 production [10]. Further, ICs formed 
between an allergen, and its specific IgG can be inter-
cepted by FcγRIII expressed on antigen-presenting cells, 
which leads to an increase in Th2 signalling through up-
regulation of IL-33 [11]. In fact, this can be extrapolated 
to any IC with IgG, since the up-regulation of IL-33 is 
mediated by the Fc:FcR binding and not the complexed 
antigen. IL-33 has been shown to activate resident ILC2 s 
(expressing the IL-33 receptor) to produce Th2 cytokines 
[11]. Therefore, an IC-mediated increase in Th2 signal-
ling could lead to the observed airway eosinophilia via 
activation of IL-5 producing ILC2s, subsequent lung-
homing and differentiation of EoPs, in situ.
Initial depletion of IL-5 by targeted therapy might have 
suppressed autoantigen-specific regulatory cells, thereby 
compromising the local tolerance, as per observations in 
a model of experimental autoimmune neuritis [12]. Being 
a retrospective case study, we were unable to enumerate 
regulatory cells pre- and post therapy (via flow cytom-
etry) to gauge any effect of anti-IL-5 targeted therapy 
on regulatory lymphocyte population/activity. How-
ever, compared to data collated from 15 healthy volun-
teer sputum (mean IL-10 levels: 2.9 ± 1.3 pg/mL, upper 
90% percentile 5.88  pg/mL), the study patient had low 
levels of IL-10 in sputum, that varied between 0.29 and 
0.59 pg/mL in all the samples tested between Aug-2013 
and Jun-2015. This was indicative of a ‘local’ micro-envi-
ronment with compromised immune-regulation. Indeed, 
laboratory investigations, as early as 2010, showed that 
the patient had a propensity towards local autoimmune 
response [13]. We could detect high titres of anti-eosin-
ophil peroxidase (EPX) IgG and anti-nuclear antibodies 
(ANAs, Figs. 1b, 2; see Additional file 1: online repository 
for methods) in the sputum, otherwise undetectable in 
circulation. Incidentally, there was also an increase docu-
mented for sputum B-cell activity (B-cell activating factor 
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(BAFF) levels: pre-Mepolizumab, Feb-13—19.2 pg/mL to 
post-Mepolizumab, Oct-14: 228  pg/mL). We speculate 
that increase in activated ILC2s contributed to the local 
B-cell activity since the former has recently been reported 
to activate and promote survival of B-cells in vitro [14]. 
The concurrent increase in eosinophils and autoantibod-
ies would allow spontaneous IgG-mediated eosinophil 
degranulation in the airways, an event that is known to 
be steroid-unresponsive [15]. Increased frequency of a 
steroid-unresponsive event could explain the increase in 
maintenance prednisone dose to 40 mg (Fig. 1b).
To target the lymphocytes, the patient was then treated 
with daily 150  mg azathioprine without any continual 
clinical improvement. At an all-time low FEV1 of 0.56 L 
(23% predicted), she was started on intravenous immu-
noglobulins (IVIgs, 2 g/kg weight, over 3 days, monthly) 
as an autoantibody mopping-up strategy. Post six 
monthly infusions (Nov-15) her sputum autoantibody 
titres reduced steadily, and FEV1 improved to 1.13  L 
(Fig.  2), suggesting a plausible underlying autoimmune-
type anomaly. Indeed, the autoantibody levels correlated 
with the deteriorating lung-function (FEV1) over the 
entire timeline of the case study (r  =  −0.55, P  =  0.01, 
Fig. 1b).
At the last IVIg infusion, the prednisone dose was 
reduced to 17.5 mg to assess a steroid-sparing effect. The 
lowered dose was unable to suppress the local inflamma-
tory mediators that allowed ‘lung-homing’ of lymphocytes 
and increased IL5+ ILC2s, driving an in situ eosinophilo-
poeisis evident by the concomitant increase in sputum 
eosinophils (Nov-15 Fig.  2). The exacerbation (Jan-16) 
was treated with a prednisone burst. In the absence 
of  the steroid-unresponsive IgG-induced degranulation 
post-IVIg (Nov-15), an ILC2-mediated increase in spu-
tum eosinophilia recently shown to be steroid-responsive 
[16], could be curbed by a prednisone burst. Thereafter, 
the patient was maintained at 17.5 mg of daily prednisone 
(Fig.  1b). Her recent FEV1 in Mar-16 was recorded to 
be 1.54 L (Fig. 1b). She continues to be hyperresponsive 
(PC20 methacholine <0.03  mg/mL), contributing to her 
daily symptoms and poor asthma control, ACQ of 1.5). 
She is being considered for therapy with additional IVIg 
and/or intravenous reslizumab (an IgG4 anti-IL5 mAb, 
weight-adjusted dosing) or anti-IL4Rα mAb (Dupulimab).
Fig. 2 Disease progression timeline highlighting the diverse treatment and concurrent molecular events. a Both circulating and sputum IL5+ ILC2s 
is plotted as a percentage of a total number of enumerated ILC2s (protocol described in [5]), along with sputum IL-5 levels (see Additional file 1: 
online repository for methods) on the right Y axis. b Representative images of the ANA reactivities of sputum samples collected at the given dates is 
presented here (see Additional file 1: online repository for method and validation)
Page 5 of 6Mukherjee et al. Allergy Asthma Clin Immunol  (2017) 13:2 
Conclusion
To our knowledge this is the first case report of an anti-
IL-5 therapy leading to worsening of clinical symptoms 
in eosinophilic severe asthma. In summary, we provide 
evidence that normal blood eosinophil counts post low-
dose Mepolizumab therapy does not confirm that the 
eosinophil-driven disease process is adequately controlled. 
Indeed, sputum was demonstrated to be superior to blood 
in monitoring response to therapy. Although a direct evi-
dence of in vivo IC-mediated injury could not be demon-
strated, a concurrent increase in sputum IL-5 (whether in 
a free-form or bound) and IL5+ ILC2 population provided 
indirect evidence of possible ICs acting as ‘cytokine depots’, 
supporting in situ eosinophilopoiesis. And finally, we dem-
onstrated that Mepolizumab, at the current prescribed dose 
and delivery platform, may precipitate steroid-insensitivity 
by triggering steroid-unresponsive auto-inflammatory 
mechanisms, especially in patients who are predisposed to 
it. Further studies are necessary to understand the airway 
pharmacokinetics of novel mAbs, effective dosing strate-
gies particularly whether they have to be guided by anti-
gen-concentrations or body weight, and the appropriate 
therapy for patients with inadequate or worsening clinical 
responses with the monoclonal antibodies.
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